Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division. Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. RWE protocol that may not meet regulator expectations reads as Proceed under protocol once a boxed-warning proposal from the review division is lined up to the same Pharma & Life Sciences population. 2. RWE protocol that may not meet regulator expectations is closer to Pause the pathway after a boxed-warning proposal from the review division; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in RWE protocol that may not meet regulator expectations for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study. 4. RWE protocol that may not meet regulator expectations is missing the fact pediatric-plan strategist needs after a boxed-warning proposal from the review division; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against a boxed-warning proposal from the review division and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division). The follow-on Clinical and Evidence Strategy action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in RWE protocol that may not meet regulator expectations, then the action for pediatric-plan strategist - Hypothesis scorecard against RWE protocol that may not meet regulator expectations: supported / rejected / untestable - Owner and next date for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study - What changes to drop a secondary if a boxed-warning proposal from the review division is later withdrawn